We have developed a revolutionary platform technology that induces tumor into necrosis and converts the cancer into a therapeutic vaccine. Our platform significantly enhances the therapeutic benefit of immunotherapy, and can be leveraged to treat nearly all solid tumors. We have the unique advantage in solving the challenge of immunotherapy in liver metastasis.